In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Centre developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumours.

The study was led by Jun Wei, M.D., Ph.D., assistant professor of Lymphoma & Myeloma, and principal investigator Robert Z. Orlowski, M.D., Ph.D., professor of Lymphoma & Myeloma.

Wei presented the results at the 67th American Society of Haematology (ASH) Annual Meeting and Exposition (Abstract 388).

“There is tremendous promise in the way 77A is capable of rewiring the immune system, enabling it to respond effectively against multiple cancers,” Wei said.

“Our findings offer a new pathway to immunotherapy and patient treatment.”

How does the 77A antibody work to activate the immune system against cancer?

The 77A antibody targets HSP70, a heat shock protein that helps tumours evade the immune system.

HSP70 often is overproduced in certain blood cancers and solid tumours, contributing to a hostile tumour environment by suppressing immune responses and promoting cancer cell survival.

In laboratory models, 77A demonstrated strong antitumor effects by enhancing the activity of both innate and adaptive immune cells, including natural killer (NK) cells and T cells.

The antibody improved the ability of immune cells to detect and destroy cancer cells, and it worked well in combination with other treatments, such as chemotherapy, radiation therapy and immune checkpoint blockade.

It also showed potential to pair with adoptive T cell therapy, a cutting-edge approach where patients receive lab-grown immune cells to target cancer cells.

What are the next steps for this research?

Importantly, 77A was effective in laboratory models of multiple cancer types, and early tests with human immune cells showed it could enhance immune responses in healthy donors.

These findings pave the way for clinical trials and suggest 77A could become a versatile new therapeutic option that warrants further investigation.

"These results give us confidence that 77A could become a versatile immunotherapy,” Orlowski said.

“Our next step is to advance a humanised version of this antibody into clinical trials to evaluate its potential in patients across multiple cancer types.”

The 77A humanised antibody is under development and expected to move into clinical trials.

Source: University of Texas M. D. Anderson Cancer Center